| 1 |
Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline[J]. Neurology, 2011,77(5):461-468.
|
| 2 |
Sakurai H, Hanyu H, Sato T, et al. Vascular risk factors and progression in Alzheimer's disease [J]. Geriatr Gerontol Int, 2011,11(2): 211-214.
|
| 3 |
Li Jing, Zhang Meng, Xu Zhi-Qiang, et al. Vascular risk aggravates the progression of Alzheimer's disease in a Chinese cohort[J].J Alzheimers Dis,2010,20(2):491-500.
|
| 4 |
Gabor Abellan van K, Rolland Y, Nourhashemi F, et al. Cardiovascular disease risk factors and progression of Alzheimer's disease[J]. Dement Geriatr Cogn Disord, 2009,27(3):240-246.
|
| 5 |
Qiao Jin, Lu Wen-Hui, Wang Jin, et al.Vascular risk factors aggravate the progression of Alzheimer’s disease:a 3-year follow-up study of chinese population[J]. AM J Alzheimers Dis Other Demen,2014, 29(6): 521-525.
|
| 6 |
Helzner EP, Luchsinger JA, Scarmeas N, et al.Contribution of vascular risk factors to the progression in Alzheimer disease [J].Arch Neurol, 2009,66(3):343-348.
|
| 7 |
Arntzen K A.,Schirmer H, Wilsgaard T, et al. Impact of cardiovascular risk factors on cognitive function: The Troms study[J]. Eur J Neurol, 2011, 18(5):737–743.
|
| 8 |
Weiner M F, Hynan L S, Rossetti H, et al. The relationship of cardiovascular risk factors to Alzheimer disease in Choctaw Indians[J]. Am J Geriatr Psychiatry,2011,19(5):423-429.
|
| 9 |
Kimm H, Lee P H, Shin Y J, et al. Mid-life and late-life vascular risk factors and dementia in Korean men and women[J]. Arch Gerontol Geriatr, 2011, 52(3):117-122.
|
| 10 |
Schneider P, Buerger K, Teipel S, et al. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer’s disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. [J]．Biol Psychiatry, 2011,70(2):145–151.
|
| 11 |
Muther J, Abholz HH, Wiese B, et al. Are patients with dementia treated as well as patients without dementia for hypertension, diabetes, and hyperlipidaemia? [J].Br J Gen Pract，2010,60(578):671-674.
|
| 12 |
Targosz-Gajniak M, Siuda J, Ochud S. et al. Cerebral white matter lesions in patients with dementia – from MCI to severe Alzheimer's disease[J]. J Neurol Sci,2009,283(1-2): 79–82.
|
| 13 |
Querfurth H W, LaFerla F M. Mechanisms of disease :Alzheimer’s disease[J]. N Engl J Med, 2010,362(4): 329-344.
|
| 14 |
张映琦，周华东，李敬诚，等．重庆市老年人认知功能障碍的社区调查[J]．重庆医学，2002,31(10): 992-993.
|
| 15 |
Razay G, Williams J, King E, et al. Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study[J]. Dement Geriatr Disord,2009,28(1):70-74.
|
| 16 |
Kume K, Hanyu H, Sato T, et al. Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study[J]. J Neurol,2011,258 (7): 1295-1303.
|
| 17 |
Ninomiya T, Ohara T, Hirakawa Y, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study[J]. Hypertension, 2011,58(1) :22-28.
|
| 18 |
Sujuan G, Yinlong J, Frederick W, et al. Hypertension and cognitive decline in rural elderly Chinese[J]. J Am Geriatr Soc,2009,57(6):1051–1057.
|
| 19 |
Davis RN, Massman PJ, Doody RS, et al. Effects of blood pressure on neuropsychological functioning in Alzheimer’s disease[J]. Arch Clin Neuropsychol，2003,18 (1):19–32.
|
| 20 |
Grassi D, Ferri L, Cheli P, et al. Cognitive decline as a consequence of essential hypertension[J]. Curr Pharm Des,2011,17(28):3032-3038.
|
| 21 |
Vicario A, del Sueldo M A, Zilberman J M, et al. Cognitive evolution in hypertensive patients: a six-year follow-up[J]. Vasc Health Risk Manag，2011，7(5):281-285.
|
| 22 |
Birns J, Morris R, Jarosz J, et al. Hypertension-related cognitive decline: is the time right for intervention studies? [J]. Minerva Cardioangiol，2009，57(6):813-830.
|
| 23 |
Mahanandeeshwar G, James RP, Kenneth LB, et al. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors I [J]. Brain Res,1997, 771(1):89–103.
|
| 24 |
Mahanandeeshwar G, Alvin V T, James R, et al. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. Part II[J]. Brain Research,1997,771(1):104–114.
|
| 25 |
Elias MF, Wolf PA, D’Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study[J]. Am J Epidemiol, 1993,138(6):353-364.
|
| 26 |
Elias PK, Elias MF, D' Agostino RB, et al. NIDDM and blood pressure as risk factors for poor cognitive performance: the Framingham Study[J]. Diabetes Care, 1997, 20(9):1388–1395.
|
| 27 |
Cacciatore F, Abete P, Ferrara N, et al. The role of blood pressure in cognitive impairment in an elderly population. Osservatorio Geriatrico Campano Group[J].J Hypertens, 1997, 15(2) : 135-142.
|
| 28 |
Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men[J]. Hypertension, 1998,31(3):780-786.
|
| 29 |
Launer LJ, Masaki K, Petrovitch H, et al. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study[J]. JAMA,1995,274(23):1846–1851.
|
| 30 |
张钰聪，汤哲．北京市社区老年人群血压水平与认知功能变化的4年纵向研究[J]．中华流行病学杂志, 2004, 25 (10) : 833-835.
|
| 31 |
Bermejo-Pareja F, Benito-Leon J, Louis E D, et al. Risk of incident dementia in drug-untreated arterial hypertension: a population-based study[J]. J Alzheimers Dis, 2010,22(3):949-958.
|
| 32 |
Thomas G P. Does treating hypertension prevent dementia? [J]. J Clin Hypertens, 2008,10(11):866-870.
|
| 33 |
Shah K, Qureshi SU, Johnson M, et al.Does use of antihypertensive drugs affect the incidence or progression of dementia? a systematic review[J].Am J Geriatr Pharmacother, 2009,7(5):250–261.
|
| 34 |
Qiu C, Bengt W, Fastbom J, et al. Combined effects of APOE genotype,blood pressure,and antihypertensive drugs use on incident AD[J].Neurology,2003,61(5):655-660.
|
| 35 |
Prince M J, Bird A S, Blizard R A, et al. Is the congnitive function of older patients affected by antihypertensive treatment/result from 54 months of the medical research council’s trial hypertension in older adults[J]. BMJ,1996,312(7034):801-805.
|
| 36 |
Olivier H, Françoise F.Treatment of hypertension and prevention of dementia [J]. Alzheimers Dement, 2005, 1(1):30-37.
|
| 37 |
Masatoshi F, Setsuro I, Kenichiro F, et al.Cerebral blood in flow and brain function hypertension[J]. Hypertens Res, 1995, 18(2):111-117.
|
| 38 |
Veglio F, Paglieri C, Rabbia F, et al. Hypertension and cerebrovascular damage [J]. Atherosclerosis, 2009, 205(2):331–341.
|
| 39 |
Tohda M, Suwanakitch P, J eenapongsa P, et al. Expression changes of the mRNA of Alzheimer’s disease related factors in the permanent ischemic rat brain [J]. Biol Pharm Bull, 2004, 27 (12) :2021-2023.
|
| 40 |
郑莹，赵风娣，闫福岭．慢性低氧低糖培养对脑微血管内皮细胞RAGE和LRP-1表达的影响[J]．中国临床神经科学，2008,16(3)：297-301
|
| 41 |
Carnevale D, Lembo G. Alzheimer-like' pathology in a murine model of arterial hypertension[J]. Biochem Soc Trans, 2011，39(4):939-944.
|
| 42 |
Gentile MT, Poulet R, Di Pardo A, et al. Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension[J]. Neurobiol Aging,2009,30(2):222–228.
|
| 43 |
Qiao Jin, Ma Aiqun, Lu WenHui, et al.Increased expression of β-Amyloid peptide 42 in the hippocampus correlates with cognitive impairment in spontaneously hypertensive rats[J]. Am J Hypertens, 2014, 27(8)：1127
|
| 44 |
Hoffman L B, Schmeidler J, Lesser G T, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons[J]. Neurology, 2009,72(20):1720-1726.
|
| 45 |
Arvanitakis Z, Wilson R S, Bienias J L, et al.Diabetes mellitus and risk of alzheimer disease and decline in cognitive function[J].Arch Neurol,2004,61(5):661-666.
|
| 46 |
Pelia R, Rodriguez BL, Launer LJ, et al. Type 2 diabetes,APOE gene,and the risk for dementia and related pathologies ：The Homolulu- Aisa Asia Aging Study[J]．Diabetes,2002,51(4):1256-1262.
|
| 47 |
Luchsinger JA, Reitz C, Honig LS, et al.Aggregation of vascular risk factors and risk of incident Alzheimer disease[J]. Neurology,2005,65(4):545-551.
|
| 48 |
Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes Alzheimer disease and vascular dementia：a population-based-neuropathologic study. [J] Neurology, 2010, 75(13):1195-1202.
|
| 49 |
Escribano L, Simon A M, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer’stransgenic mice: mechanisms involving a reduced amyloid and tau pathology[J]. Neuropsychopharmacology, 2010, 35(7) : 1593-1604.
|
| 50 |
Risner M E, Saunders A M, Altman J F, et al. Efficacy of rosiglitazone in a genetically defined population with mild- to- moderate Alzheimer’s disease efficacy of rosiglitazone in age- netically defined population[J]. Pharmacogenomics J, 2006, 6(4) : 246-254.
|
| 51 |
Rivera E J, Gold in A, Fulmer N, et al. Insulin and insulin like growth factor express ion and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine[J]. J A lzheimers Dis, 2005, 8 (3) : 247-268.
|
| 52 |
Craft S.The role of metabolic disorders in Alzheimer disease and vascular dementia[J]. Arch Neurol, 2009,66(3):300-305.
|
| 53 |
Steen E, Terry B M, Rivera E J, et al. Impaired insulin and insulin like growth factor expression and signaling mechanisms in Alzheimer' s disease is this type 3 diabetes? [J]. J Alzheimer Dis, 2005,7 (1) :63-80.
|
| 54 |
Origlia N, Arancio O, Domenici L, et al. MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE[J]. Expert Rev Neurother, 2009,9 (11) : 1635-645.
|
| 55 |
王苗，朱梅佳，赵张宁．不同年龄糖尿病大鼠脑组织LRP-1表达与Aβ1-40的相关性[J]. 山东大学学报（医学版),2010,48(3):19-23.
|
| 56 |
Pappolla MA, Bryant-Thomas TK, Herbert D, et al.Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology[J]. Neurology, 2003, 61(2):199-205.
|
| 57 |
Sjögren M, Mielke M, Gustafson D, et al.Cholesterol and alzheimer’s disease—is there a relation? [J].Mechanisms of Ageing and Development[J]. Mech Aqeinq Dev,2006，127(2)：138–147.
|
| 58 |
Hoffman L B, Schmeidler J, Lesser G T, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons[J]. Neurology,2009,72(20):1720-1726
|
| 59 |
Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later [J]. Dement Geriatr Cogn Disord,2009,28(1):75-80.
|
| 60 |
Honig LS, Kukll W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer' s Coord inating Center[J]. Neuro logy, 2005, 64(3): 494-500.
|
| 61 |
Helmuth L. New therapies: New Alzheimer’s treatments that may ease the mind [J]. Science, 2002, 297(5585): 1260-1262.
|
| 62 |
Roher AE, Kuo YM, Kok john KM. Amyloid and lipids in the pathology of Alzheimer disease[J]. Amyloid, 1999, 6(2): 136-145.
|
| 63 |
Schneider A, Schulz S, Chaeffer W, et al. Cholesterol depletion reduces aggregation of amyloid betapeptide in hippocampal neurons[J]. Neurobiol Dis, 2006, 23(3): 573-577.
|
| 64 |
方传勤，周华东，李敬诚，等．高胆固醇对AD大鼠神经元缺失和Tau蛋白异常磷酸化的影响[J]．中华神经医学杂志, 2009, 8(4):359-362.
|
| 65 |
Isobe C, Murata T, Sato C, et al. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer’s disease and Pakinson’s disease [J]．Life science,2005, 77(15): 1836-1843.
|
| 66 |
Guidi I, Galimberti D, Venturelli E, et al. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients [J]. Neurobiol Aging, 2005, 26(6):789-794.
|
| 67 |
Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer' s disease [J]. New Engl J Med, 2002,346(7): 476-483.
|
| 68 |
Arioğul S, Cankurtaran M, Dağli N, et al. Vitamin B12, folate, homocysteine and dementia: are they really related? [J]．Arch Gerontol Geriatr, 2005, 40(2):139-146.
|
| 69 |
Fuso A, Seminara L, Cavallaro RA, et al. S- Adensylmethioninesteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta–amyloid produvtion.Mol. Cell[J]．Neurosci, 2005, 28(1): 195-204.
|
| 70 |
Pacheco-Quinto J, Rodriguez de Turco, DeRosa S, et al. Hyerhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels [J]. Neurobiol Dis,2006, 22(3): 651-656.
|
| 71 |
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders[J].Nat Rev Neurosci,2011, 12(12): 723-738.
|